Once-weekly GLP-1R agonists: Moving the goal posts
Research output: Contribution to journal › Article
Authors
Colleges, School and Institutes
External organisations
- Birmingham Health Partners
- Department of Geriatric Medicine, Heart of England NHS Foundation Trust, Solihull Hospital, Birmingham, UK.
- Aston University
Abstract
Glucagon like peptide-1 receptor (GLP-1R) agonists for the treatment of type 2 diabetes were first introduced to Europe and the USA in 2005.1 Since then, these compounds have become well-established treatment options in the management of type 2 diabetes.2 GLP-1 R agonists have several attractive features including potent and sustained glucose lowering, low risk of hypoglycaemia because of their glucose-dependent effects on insulin and glucagon secretion, sustained weight loss, and a favourable effect on cardiovascular risk factors together with reduction in cardiovascular event rates (liraglutide and semaglutide).
Details
| Original language | English |
|---|---|
| Pages (from-to) | 260-261 |
| Journal | The Lancet Diabetes and Endocrinology |
| Volume | 6 |
| Issue number | 4 |
| Publication status | Published - 31 Jan 2018 |